Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01682213 |
|
Recruitment Status
:
Active, not recruiting
First Posted
: September 10, 2012
Last Update Posted
: June 14, 2017
|
Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Comprehensive Cancer Network
Novartis
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | September 2018 |
| Estimated Study Completion Date : | September 2018 |